Clinical trials: Upper Endoscopy
Gastrointestinal Endoscopy, Gastrointestinal Polypectomy
Dose Rate Range Finding Study of Propofol for minimal-to Moderate Sedation on Upper & Lower Endoscopic Tests
Phase IIB study to find the optimal dose rate range of propofol to maintain minimal-to-moderate sedation for diagnostic gastrointestinal endoscopy and gastrointestinal polypectomy.
- Trial name
- NCT01189604
- Testing
- ICI35,868 (propofol)
- Where
- 2 sites in Japan
- Volunteers
- 123 people
- Sponsor
- AstraZeneca
Gastroduodenal Ulceration
Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects
This trial is a Phase 2, randomized, controlled study to compare the degree of mucosal injury after the oral administration of an investigational product, PL2200, and a marketed 325 mg immediate-release aspirin product.
- Trial name
- NCT01646814
- Testing
- PL2200, Aspirin tablets
- Where
- 10 sites in United States
- Volunteers
- 247 people, healthy volunteers welcome
- Sponsor
- PLx Pharma
Upper Gastrointestinal Symptoms
Comparative Study of MCCE With/Without Tether vs Conventional Upper Endoscopy in Patients With Upper Abdominal Symptoms
A prospective single blinded, tandem study, comparing a magnetically controlled capsule with or without a tether (MCC or MCC-T) with conventional upper endoscopy for the diagnosis of patients with upper abdominal symptoms.
- Trial name
- NCT04605302
- Testing
- MCC/MCC-T, Standard gastroscopy
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- AnX Robotica Corp.
Procedural Sedation, Endoscopy
Dose-Finding Safety Study Evaluating Remimazolam (CNS 7056) in Patients Undergoing Diagnostic Upper GI Endoscopy
The purpose of this study was to assess the safety and efficacy of CNS 7056 as a procedural sedative at three dose levels compared to midazolam during a diagnostic upper GI endoscopy.
- Trial name
- NCT00869440
- Testing
- CNS 7056, Midazolam
- Where
- 7 sites in United States
- Volunteers
- 100 people
- Sponsor
- Paion UK Ltd.
Upper Gastrointestinal Mucosal Damage
Endoscopic Evaluation of Upper Gastrointestinal (GI) Mucosal Damage Induced by PL-2200 Versus Aspirin in Healthy Volunteers
To determine the gastrointestinal safety of PL-2200 versus immediate-release aspirin by assessing endoscopic gastroduodenal mucosal injury at approved daily cardiac-protective doses of aspirin (325 mg) in normal healthy…
- Trial name
- NCT00872534
- Testing
- acetylsalicylic acid
- Where
- 6 sites in United States
- Volunteers
- 204 people, healthy volunteers welcome
- Sponsor
- PLx Pharma